Chief Medical Officer (7) · Xenon Pharmaceuticals Inc. (XENE)

Ernesto Aycardi

A named executive officer of Xenon Pharmaceuticals in every fiscal year CompBrief holds from FY2018 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,106,739

Salary $434,700Stock awards $0

FY2019: $1,072,977

3rd of 3 named executive officers at Xenon Pharmaceuticals by FY2020 total.

3 named officers on file for Xenon Pharmaceuticals, FY2020

Ernesto Aycardi’s pay file — $29

  • 3 fiscal years of pay, line by line
  • XENE’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Xenon Pharmaceuticals’s whole pay program stands against its peers

  • Xenon Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on XENE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2021 (DEF 14A).

Free

Get Ernesto Aycardi’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Ernesto Aycardi compensation by year

Xenon Pharmaceuticals Summary Compensation Table · all 3 fiscal years held
In US dollars, as Xenon Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020
Salary$316,667$419,991$434,700
Bonus$30,000$0$0
Stock awards$0$0$0
Option awards$169,702$418,192$500,067
Non-equity incentive$158,333$210,000$147,798
Pension and deferred compensation$0$0$0
All other$17,309$24,794$24,174
Total$692,011$1,072,977$1,106,739

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Xenon Pharmaceuticals Inc. DEF 14A filed April 28, 2021, accession 0001564590-21-021327, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Xenon Pharmaceuticals Inc. filed document, accession 0001564590-21-021327. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2021.

$692K
$1.1M
$1.1M
FY18
FY19
FY20
SalaryBonusNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option65,000—$11.58
Option14,584—$4.65
Option36,112—$9.44

Per the Outstanding Equity Awards at Fiscal Year-End table in Xenon Pharmaceuticals Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Xenon Pharmaceuticals’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Simon PimstoneChief Executive Officer$2,941,911
Ian MortimerPresident and Chief Financial Officer$1,783,084
Ernesto Aycardi · this pageChief Medical Officer (7)$1,106,739

The full Xenon Pharmaceuticals compensation record

free company brief

This page is one person within Xenon Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Xenon Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Ernesto Aycardi's compensation dossier · One-time report. No refunds.